Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.72 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | NOS3 | P29474 | 3/20 | 0.53 |
| ▸ | NOS2 | P35228 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | THPO | P40225 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | OGT | O15294 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11045421 | 0.93 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL11256608 | 0.84 | KMO (1.00) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL9680309 | 0.84 | KMO (0.59) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL5536703 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL6164657 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL528197 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL522196 | 0.78 | NOS1 (0.53) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL7067142 | 0.78 | KMO (0.52) | KMONOS1NOS3NOS2LMNA | |
| Bromchlorenone SCHEMBL637478 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA | |
| SCHEMBL5536706 | 0.78 | KMO (0.72) | KMONOS1NOS3NOS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4997920-A | Dyeing polyolefins | CIBA-GEIGY CORPORATION (US) | 1991-03-05 | — | — | US | claimed |
| US-4670486-A | Polymer composition pigmented with copper or nickel complexes of ligands containing a semicarbazone moiety | CIBA-GEIGY CORPORATION (US) | 1987-06-02 | — | — | US | claimed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-8262949-B2 | Long wavelength shifted benzotriazole uv-absorbers and their use | BASF SE (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8262949-B2 | Long wavelength shifted benzotriazole uv-absorbers and their use | BASF SE (DE) | 2012-09-11 | — | — | US | disclosed |
| US-4220586-A | FASTNESS TO LIGHT, OVER-LACQUERING, MIGRATION, WEATHERING, AND HEAT | CIBA-GEIGY CORPORATION (US) | 1980-09-02 | — | — | US | disclosed |
| EP-0006154-A1 | Monoazo pigments and their use in colouring high molecular-weight organic material | CIBA-GEIGY AG (CH) | 1980-01-09 | — | — | EP | disclosed |
| EP-0000737-A1 | Monoazo pigments of the acetoacetylamino benzimidazolone series, their preparation and their use for colouring organic material of high molecular weight | CIBA-GEIGY AG (CH) | 1979-02-21 | — | — | EP | disclosed |
| US-4116959-A | ISOINDOLINE PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4088641-A | YELLOW TO RED SHADES | CIBA-GEIGY CORPORATION (US) | 1978-05-09 | — | — | US | disclosed |
| US-4052410-A | YELLOW, PLASTICS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-4012371-A | Benzinaldazolyl-, quinolonyl-, or phenmorpholonylazo-3-cyano-4-methyl-1,2-[1',2']-benz-[4',5']-imidazolo-6-hydroxypyridine colorants | CIBA-GEIGY CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
| US-3979386-A | YELLOW, COLORFASTNESS | CIBA-GEIGY CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
| US-3956266-A | DISAZO DYES | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KMO 462/4885NOS1 1289/4885NOS3 1955/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KMO 197/4885NOS1 2068/4885NOS3 1854/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KMO 462/4885NOS1 1289/4885NOS3 1955/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | KMO 386/4885NOS1 1266/4885NOS3 1832/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | KMO 386/4885NOS1 1266/4885NOS3 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.